Related by context. All words. (Click for frequent words.) 84 Completes Patient Enrollment 84 Receives Orphan Drug Designation 83 Improves Survival 83 Submits NDA 83 Meets Primary Endpoint 82 Prolongs Survival 82 Drug Candidate 82 Initiates Clinical Trial 82 Completes Enrollment 81 Significantly Reduces 81 Study Evaluating 81 Shows Promising 81 Significantly Improves 81 Achieves Primary Endpoint 81 Demonstrates Positive 81 Files IND 81 FDA Clears 81 FDA Approvals 80 Initiates Clinical 80 Initiates Enrollment 80 Study Demonstrates 80 Initiates Phase II 80 Phase 2b Clinical Trial 80 Presents Preclinical Data 80 Gets FDA Clearance 80 Initiate Clinical Trial 79 Presents Positive 79 Improves Outcomes 79 Shows Efficacy 79 Reduces Risk 79 Patients Treated With 79 Demonstrates Potential 79 Adjuvant Treatment 79 Phase IIb Trial 79 Granted Orphan Drug 79 Novel Oral 79 Teva Provides Update 79 Cholesterol Lowering Drug 79 Present Preclinical Data 79 Successfully Completes Phase 79 FDA Okays 79 Phase 2b Trial 78 Receives Approvable Letter 78 Initiates Phase III 78 Initiates Clinical Trials 78 Shows Promise Against 78 Phase IIb Clinical Trial 78 Announces FDA Clearance 78 Orally Active 78 Phase III Trial 78 Clinical Trial Results 78 Newly Diagnosed Multiple Myeloma 78 Protease Inhibitor 78 Patients Treated 78 Antitumor Activity 78 Drug Shows Promise 78 Single Dose 78 Phase III Clinical Trial 78 Significantly Improved 78 Showed Significant 78 Patient Enrollment 78 PRN FDA Approves 78 Lupus Drug 77 Plaque Psoriasis 77 Data Suggest 77 Previously Treated 77 Shows Statistically Significant 77 Patients Receiving 77 Presents Preclinical 77 Adjunctive Therapy 77 Oral Fingolimod 77 Phase IIa Clinical Trial 77 Treatment Naïve 77 Severe Sepsis 77 Phase 2a Trial 77 FDA APPROVES 77 Advanced Melanoma 77 Demonstrated Significant 77 Clinical Trial Evaluating 77 Receives Orphan Drug 77 Trial Evaluating 77 Investigational Compound 77 Receives FDA Clearance 77 Receives Milestone Payment 77 Survival Benefit 77 IND Application 77 Chronic Hepatitis C 77 Pooled Analysis 77 FDA Accepts 77 Vaccine Adjuvant 77 Submits Supplemental 77 HCV Protease Inhibitor 76 Demonstrates Sustained 76 Announces Tentative Approval 76 Hypertensive Patients 76 Combination Treatment 76 Psoriasis Drug 76 Improves Quality 76 Begins Dosing 76 Demonstrates Statistically Significant 76 Pivotal Phase III 76 Demonstrates Efficacy 76 Shows Promise 76 Patients Undergoing 76 Combination Therapy 76 Mylan Receives Approval 76 Commences Phase 76 Treated Patients 76 Submits IND 76 Appears Safe 76 Enrolls First 76 Adjuvant Chemotherapy 76 Hsp# Inhibitor 76 Lowers Risk 76 Announce License Agreement 76 Clinical Outcome 76 Initiate Phase 76 TO AVOID PREGNANCY WHILE 75 Study Shows Benefits 75 Demonstrates Potent 75 Elderly Patients 75 Immunomedics Announces 75 Drug Fails 75 NDA Submission 75 Low Dose 75 Combo Therapy 75 Submits Biologics License Application 75 Licenses Novel 75 Proven Effective 75 Confirms Efficacy 75 Epilepsy Drug 75 Relapsing Multiple Sclerosis 75 Spectrum Pharmaceuticals Announces 75 Files Patent Application 75 Files Investigational 75 Kinase Inhibitor 75 Mg Usa 75 Initiates Dosing 75 Proves Effective 75 Preclinical Data 75 Randomized Trials 75 Begins Shipment 75 Is Well Tolerated 75 Improve Survival 75 Initiates Phase 2b 75 Combination REOLYSIN R 75 Initiates Phase 75 Novel Compound 75 Dose Escalation 75 Reports Preclinical Data 75 Gout Drug 75 IN PATIENTS WITH 75 Pivotal Study 75 First Patient Dosed 75 Receives SFDA Approval 75 Demonstrate Significant 75 Rheumatoid Arthritis Drug 75 Recombinant Human 75 Investigational Oral 75 Receives Fast Track 75 Osteoporosis Drug 75 Therapeutic Competitors Companies 75 Long Term Efficacy 75 Launches Generic Version 75 Randomized Double Blind 75 Monotherapy 75 Levels Linked 75 First Patient Enrolled 75 JAK2 Inhibitor 75 Reduced Risk 75 Therapy Reduces 75 Pivotal Phase 75 Patients Suffering 74 Bosutinib 74 Announces Poster Presentations 74 Patent Covering 74 Therapy Improves 74 Blood Pressure Drug 74 Presents Positive Preclinical 74 Initiate Phase III 74 Regains NASDAQ 74 Anti Tumor 74 Expanded Indication 74 BioSante Pharmaceuticals Announces 74 Announce Collaboration Agreement 74 Inhaled Corticosteroids 74 Generic Versions 74 Mouse Model 74 Demonstrates Superior 74 Receives Positive Opinion 74 Osteoporosis Treatment 74 Lung Cancer Drug 74 Increases Risk 74 Announces Initiation 74 Diabetic Neuropathy 74 Inhibits 74 Treatment Reduces 74 FDA Approves 74 Generic Version 74 Study Reinforces 74 Earns Milestone Payment 74 Node Positive 74 Achieves Milestone 74 Phase 2a Clinical Trial 74 Predict Risk 74 Transdermal Patch 74 Investigational Treatment 74 Announces Immediate Availability 74 Reveals Positive 74 Study Showed 74 Controlled Trial 74 Antitumor 74 II Clinical Trial 74 Tyrosine Kinase Inhibitor 74 PPD Declares 74 Fracture Risk 74 Taro Receives 74 Significantly Reduced 74 Dramatically Increases 74 Sirolimus Eluting Stent 74 Submits Response 74 Announces Publication 74 RNAi Therapeutic 74 Develop Novel 74 Versus Placebo 74 Completes Dosing 74 VIVUS Announces 74 Pediatric Patients 74 Rheumatoid Arthritis Patients 74 Slow Progression 74 Fast Track Status 74 Receives NASDAQ 74 Treating Chronic 74 Breast Cancer Recurrence 74 Abstract Accepted 74 Investigational Drug 74 Collaborators Present 74 Diabetic Foot Ulcer 74 Complicated Skin 74 Phase 1b Clinical Trial 74 Treatment Regimen 74 Phase III Trials 74 Systemic Delivery 74 Renal Cell Carcinoma 74 Heart Failure Patients 74 Polymerase Inhibitor 74 Prostate Cancer Vaccine 74 Arthritis Drug 74 Receives CE Marking 74 Migraine Drug 74 Flamel Technologies Announces 74 Hormone Receptor Positive 73 Reduces Mortality 73 Kaydon Corporation Announces 73 Preclinical Study 73 Crofelemer budesonide foam 73 Study Shows Significant 73 JAK Inhibitor 73 Interferon Alpha 73 R lenalidomide 73 Statistically Significant 73 Test Detects 73 Improved Survival 73 Oral Calcitonin 73 Strengthens Balance Sheet 73 Pivotal Trial 73 Prostate Cancer Patients 73 Milestone Payment 73 platform HDL Mimetic 73 Previously Untreated 73 Phase Ib Clinical Trial 73 Vitrasert R 73 Clinical Trial Data 73 Novel Inhibitor 73 Adjuvant Therapy 73 Efficacy Results 73 Vaccine Protects Against 73 Study Validates 73 Randomized Clinical Trials 73 Fungal Infections 73 Well Tolerated 73 Study Evaluates 73 Subgroup Analysis 73 Anti Tumor Activity 73 Statin Drugs 73 Significantly Increases 73 Randomized Double blind 73 IND Filing 73 Awarded Patent 73 Confirmatory Phase 73 Meta Analysis 73 Settle Patent Litigation 73 Relapsed Refractory 73 Therapeutic Competitors companiesandmarkets.com adEgemonye 73 AnaSpec Introduces 73 Desvenlafaxine Succinate 73 Study Proves 73 Rotavirus Vaccine 73 Provides Update Regarding 73 Drug Combo 73 Sign License Agreement 73 Disease Modifying 73 Advanced Prostate Cancer 73 Viral Load 73 FDA Panel Recommends 73 Oral Laquinimod 73 Receive Milestone Payment 73 Refractory Hodgkin Lymphoma 73 Medoxomil 73 Treatment Experienced 73 Metastatic Melanoma 73 Provides Guidance 73 Board Authorizes 73 Pharmacokinetics PK 73 Parathyroid Hormone 73 Cites Positive 73 Therapeutic Efficacy 73 Kidney Transplant Patients 73 Cell Transplants 72 Treat Anemia 72 By JENNIFER LEARN 72 Inflammatory Markers 72 Submits Application 72 Effectively Treats 72 Equity Funds Declare 72 Knee Osteoarthritis 72 Announce Merger Agreement 72 Osteoporosis Drugs 72 Guidelines Issued 72 Receives Patent 72 Investigational Agent 72 Poniard Pharmaceuticals Announces 72 Advanced Pancreatic Cancer 72 Introduces Breakthrough 72 Commercializes 72 Novel Antibiotic 72 Receives Favorable 72 Secondary Hyperparathyroidism 72 Nicotine Vaccine 72 Predict Response 72 Study Confirms 72 Intravitreal 72 Advanced Colorectal Cancer 72 Vaginal Gel 72 Prospective Randomized 72 Oral Mucositis 72 Disease Progression 72 FDA Clearance 72 Announces Presentation 72 See CLINICAL PHARMACOLOGY 72 NICE Recommends 72 Slows Progression 72 Renal Cancer 72 Hematological Malignancies 72 vapreotide acetate 72 Chemotherapy Improves 72 Controlled Study 72 Neoadjuvant Chemotherapy 72 Sangamo BioSciences Announces 72 Inhaled Insulin 72 Tezampanel 72 Announce Licensing Agreement 72 Prophylactic Treatment 72 Metabolic Disorder 72 Announces Discontinuation 72 ALN HPN 72 Reacquires 72 Zorbtive TM 72 ODT metoclopramide HCl PEPCID 72 Treatment Resistant 72 Chemotherapy Induced 72 Licenses Patents 72 novel orally inhaled 72 SPRYCEL ® 72 Immunotherapeutic 72 Cypher Sirolimus 72 Clinical Study Shows 72 Oral Formulation 72 Multiple Myeloma Patients 72 Metastatic Colorectal Cancer 72 novel emulsion formulation 72 Jumps Higher 72 Study Indicates 72 ABLYNX 72 Announcement acc 72 Emerging Therapies 72 Kidney Function 72 J Am Coll 72 Further Validates 72 BioElectronics Announces 72 Heart Transplant Recipients 72 Vaccine Candidate 72 Unfractionated Heparin 72 Patents Covering 72 Chronic Hepatitis B 72 Univest Corporation Declares 72 Commence Phase 72 STERIS Corporation Announces 72 MOVIPREP R 72 Gene Linked 72 Lung Cancer Survival 72 Inflammatory Arthritis 72 Double Blind Placebo 72 Issues Guidance 72 Pegylated Liposomal Doxorubicin 72 Platform Enables 72 Introduces Next Generation 72 Cholesterol Drugs 72 Therapeutic Vaccine 72 Reports Positive 72 Placebo Controlled Trial 72 Genes Linked 72 Protein Linked 72 Tigecycline 72 Pafuramidine 72 TriCo Bancshares Announces 72 Hormone Refractory Prostate Cancer 72 Posaconazole 72 Obesity Linked 72 Phase 2b Study 71 Bone Metastases 71 Achieves Positive 71 Platelet Inhibition 71 Sign Licensing Agreement 71 Protects Against 71 Relapsed Multiple Myeloma 71 Patent Issued 71 Reveals Significant 71 Successfully Treated 71 Dramatically Improves 71 Jointly Announce 71 Xcytrin R 71 Premenopausal Women 71 Recurrent Breast Cancer 71 Pharmacokinetic Study 71 Protease Inhibitors 71 COMPLETES ACQUISITION OF 71 ORLive Presents 71 Relapsing Remitting Multiple Sclerosis 71 Begins Clinical Trial 71 Anticancer Activity 71 Clinical Efficacy 71 Bepreve TM 71 Castration Resistant Prostate Cancer 71 Glucose Control 71 Effective Than 71 Receptor Antagonist 71 Cholesterol Drug 71 Releases Next Generation 71 Mg Uk 71 Obese Patients 71 Fondaparinux 71 Localized Prostate Cancer 71 Gastric Cancer 71 Announces Adjournment 71 Neuroendocrine Tumors 71 Remission Maintenance 71 Invasive Fungal Infections 71 Hematological Cancers 71 Randomized Study 71 FDA Approves Drug 71 Receives Tentative Approval 71 Vascular Grafts 71 Drug Prevents 71 XPEL Announces 71 Therapeutic Competitors Report 71 PDL BioPharma Announces 71 Multiple Ascending Dose 71 Achieves Significant 71 Guidelines Recommend 71 Nanophase Announces 71 Tumor Targeting 71 Myeloma Patients 71 Announce Initiation 71 Announces Licensing Agreement 71 Delivers Unprecedented 71 Patients Enrolled 71 Therapeutic Antibody 71 COLLABORATION WITH 71 Helps Predict 71 FDA Approves Novel 71 Provides Unprecedented 71 Hepatitis C Genotype 71 myelodysplastic myeloproliferative diseases 71 5q MDS 71 LifeVantage Announces 71 Tumor Response 71 Cardiovascular Events 71 Subtypes 71 Medicure Announces 71 Randomized Double Blind Placebo 71 Unveils Groundbreaking 71 #-# Full Text 71 Inhaled Nitric Oxide 71 Receives Positive 71 Crit Rev 71 HER2 Positive Breast Cancer 71 Renal Impairment 71 Proves Successful 71 HDAC Inhibitor 71 Anti CD# Antibody 71 Reduces Cost 71 Strengthens Position 71 Schizophrenia Treatment 71 Reduces Pain 71 Shown Effective 71 Gene Variation 71 Telik Announces 71 Flagship Product 71 CYP#A# CYP#D# 71 Successfully Treats 71 First Patient Treated 71 FDA Approves Generic 71 Hemodialysis Patients 71 Lupus Nephritis 71 Dose Ranging 71 Newly Diagnosed Patients 71 Non Invasive Treatment 71 Treatment Naive Patients 71 Prove Effective 71 THERAPEUTICS 71 Brentuximab Vedotin SGN 71 Vildagliptin 71 Stent Implantation 71 Infected Patients 71 Capsules CII 71 Milestone Payments 71 Announces License Agreement 71 Patient Treated 71 Complete Remission 71 Fewer Side Effects 71 Improve Outcomes 71 Randomized Controlled Trials 71 Files Shelf Registration Statement 71 Mycophenolate Mofetil 71 Gene Variants 71 Treatment Shows Promise 71 TRANSDUR ® 71 Benign Prostatic Hyperplasia 71 Awarded Patents 71 Expand Collaboration 71 Xeloda ® 71 Collaborators Publish 71 Dose Ranging Study 71 Randomized Clinical Trial 71 Receives Complete Response 71 PROCTOCORT R 71 Bare Metal Stents 71 Demonstrates Long Term 71 AAG geldanamycin analog 71 Hydrochlorothiazide Tablets 71 Significant Improvements 71 Taglich Brothers Initiates Coverage 71 Anti Inflammatory 71 Milestone Achieved 71 Long Term Outcomes 71 Postmenopausal Women 71 Boosts Survival 71 Pulmonary Arterial Hypertension 71 Induces 71 Zicam Cold Remedy RapidMelts 70 Settles Litigation 70 Antiplatelet 70 Ovitrelle R Serostim 70 Schizophrenia Drug 70 Peginterferon 70 BIOLASE Announces 70 Contrast Agents 70 Sinks Lower 70 Randomized Phase 70 PHASE III 70 Novel Treatments 70 INDUSTRY ASSESSMENTS 70 Therapy Shows Promise 70 Colorectal Cancer Patients 70 Identifies Potential 70 Antiviral Activity 70 Carotid Stenting 70 Lung Cancer Trial 70 Progressive Multifocal Leukoencephalopathy 70 Receptor Agonist 70 Solution Achieves 70 Acute Attacks 70 Study Casts Doubt 70 Chemotherapeutic Agents 70 Tumor Growth 70 Phase 2a Study 70 Antidepressant Drug 70 Study Identifies 70 Glatiramer Acetate 70 Potent Antiviral Activity 70 Expands Capabilities 70 HER2 Positive 70 Coverage Initiated 70 Less Invasive 70 Randomized Placebo Controlled Trial 70 AVI BioPharma Announces 70 Announces Positive 70 Demonstrates Ability 70 Salix Pharmaceuticals Announces 70 Deliver Powerful 70 Introduces Enhanced 70 R Saizen R 70 FDA Warns Against 70 Injectable Drug 70 events thrombocytopenia neutropenia 70 Naive Patients 70 Small Molecule 70 Lowers Blood Pressure 70 brand ciclesonide HFA 70 Nuvelo Announces 70 Develops Novel 70 Chemotherapy Regimen 70 Hyperlipidemia 70 Heska Announces 70 TRANSDUR ™ 70 Osteoarthritis Patients 70 Guides FY# Quick Facts 70 Monoclonal Antibody 70 Q2 Loss Narrows 70 Announces Enhancements 70 Mitigates 70 Anemia Drug 70 Forecast Quick Facts 70 abacavir sulfate lamivudine 70 highly purified pasteurized 70 Elagolix 70 Aromatase Inhibitors 70 Atypical Hemolytic Uremic Syndrome 70 Vitrasert ® 70 Smoking Linked 70 Regenerative Cells 70 Study Shows Promise 70 Antidepressants Linked 70 Personalized Immunotherapy 70 Calcium Acetate 70 Genes Predict 70 STELARA TM 70 Anticancer Drug 70 MEK Inhibitor 70 Announce Availability 70 Significant Improvement 70 Diabetic Patients 70 Gentium Announces 70 Telaprevir VX 70 Oral Cladribine 70 Begin Clinical Trials 70 RNAi Therapeutics 70 Acute Ischemic Stroke 70 Awarded Qualifying Therapeutic 70 oral prodrug 70 COPEGUS R 70 Vascular Disrupting Agent 70 Asthma Treatment 70 essential thrombocythemia ET 70 Peginterferon alfa 2b 70 Declares Dividend Quick Facts 70 Atopic Dermatitis 70 Attenuates 70 Introduces Unique 70 Study Compares 70 FEMALES SHOULD BE ADVISED 70 Altera Ships 70 Autologous Stem Cell Transplantation 70 Helps Reduce 70 TNF Tumor Necrosis Factor 70 Pfizer Discontinues 70 Sustained Reduction 70 Regains Compliance 70 End Funds Declare 70 Contrast Agent 70 Seasonal Influenza Vaccine 70 Oral Spray 70 Doripenem 70 Recurrent Glioblastoma 70 Overactive Bladder 70 Telik logo TELINTRA 70 Prolongs Life 70 Physical Function 70 Key Milestones 70 Amends Agreement 70 Revises Guidance 70 Aloxi ® 70 Dry Powder Inhalers 70 Expands Portfolio 70 Minimally Invasive Treatment 70 R bisoprolol Euthyrox 70 Skin Lesions 70 Grants Orphan Drug 70 Vidaza R 70 Efficacy Trial 70 Announces Successful Completion 70 Preclinical Models 70 Pivotal Clinical Trial 70 Expands Scope 70 Receives Clearance 70 Molecular Diagnostic Test 70 Revises FY# Outlook 70 Multicenter Phase 70 Canaccord Genuity Reiterates Buy 70 Commences Phase III 70 美 通 社 70 Q3 Loss Narrows 70 candidates Azedra TM 70 Recommends Approval 70 Estrogen Therapy 70 TM Aganocide 70 Testosterone Gel 70 Myocardial Perfusion Imaging 70 pan histone deacetylase 70 Cholesterol Lowering 70 Synthetic Peptide 70 PRESENTED AT 70 Neoadjuvant 70 Am J Obstet 70 AVANIR Pharmaceuticals Announces 70 Releases Enhanced 70 Continues Momentum 70 Aliskiren 70 DOR BioPharma Announces 70 Q2 Loss Widens 70 AND ANNOUNCE 70 Metastatic Prostate Cancer 70 Bazedoxifene 70 Antimicrobial Coating 70 Lung Cancer Patients 70 NASH Huntington 70 Preclinical Efficacy 70 Left Ventricular 70 Anthracycline 70 ISSI Announces 70 Anticancer Agent 70 Interferon Beta 70 Holds Promise 70 Phase IIa Trial 70 Antiviral Drugs 70 Antigen Specific 70 MBRX 70 Tumor Cell 70 Liver Toxicity 70 Atypical Antipsychotic 70 Orthostatic Hypotension 70 Chemoradiation 70 Vertebral Fractures 70 5 FU leucovorin 70 Randomized Phase II 70 Stem Cell Treatment 70 Derma Sciences Announces 69 Obtains FDA 69 Catheter Associated 69 Carotid Artery Stenting 69 Announces Effective Date 69 Post Menopausal 69 Advanced Renal Cell 69 PDUFA Date 69 Peginterferon Alfa 2a 69 Critically Ill Patients 69 Strongly Linked 69 Novel Mechanism 69 topical gel formulation 69 Alpha interferons including 69 Updates Guidance 69 DOWNGRADE ALERT WATCH FOR 69 Projected Release Date 69 CYP#A# substrate 69 Clostridium difficile Infection 69 Integrase Inhibitor 69 Boosts Productivity 69 Vascular Inflammation 69 Lenalidomide 69 ® lenalidomide 69 R MSCRAMM 69 Anworth Announces 69 Prognostic Value 69 Metformin HCl 69 SinuNase TM 69 CONTINUES LOWER 69 Tablet Formulation 69 IIa Clinical Trial 69 Sees Steady 69 www.BYETTA.com 69 COMUNICADO DE 69 BCG refractory carcinoma 69 Danazol 69 Shingles Vaccine 69 ANADIGICS Announces 69 Bond Funds Declare 69 ST PHOTO CAROLINE 69 Explore Strategic Alternatives 69 Enlarged Prostate 69 Inc Therapeutic Competitors 69 Provide Comprehensive 69 Poorly Controlled 69 Reduce Risk 69 Targeted Therapies 69 Gastrointestinal Stromal Tumors 69 Genes Involved 69 Pruvel TM 69 Biogen Genentech 69 Premature Infants 69 Municipal Funds Declare 69 Adverse Event 69 Romiplostim 69 Drug Resistant 69 Conjugate 69 Pharmacyclics Announces 69 Interferon beta 1a 69 Extends Capabilities 69 METOZOLV TM ODT metoclopramide 69 Transplant Patients 69 Acetate Rectal Suppositories 69 Issued Patent 69 Non Responders 69 Testosterone Patch 69 novel histone deacetylase 69 Heartburn Drugs 69 Genetic Tests 69 Help Detect 69 sapropterin dihydrochloride 69 Certain DWS Closed 69 Income Funds Declare 69 Differentiates 69 Eszopiclone 69 Antifungal 69 Virus Infection 69 XL# anticancer compounds 69 Cutaneous T 69 oncolytic virus therapies 69 Liver Transplant Patients 69 Inhalation Solution 69 Resubmission 69 Sustained Release 69 Venous Thrombosis 69 Drug Eluting 69 Treatment Naïve Patients 69 에 을 69 Confirms Commitment 69 Melphalan 69 Hospital Acquired Pneumonia 69 Anti Clotting Drug 69 Synta Announces 69 Spinal Fusion 69 Supplemental Biologics License Application 69 Pegloticase 69 lexidronam injection 69 Receives Unsolicited 69 Postmenopausal Osteoporosis 69 Nasdaq Listing Requirements 69 Extended Release 69 Delivers Breakthrough 69 Prospective Multicenter 69 Drug Coated Stent 69 Soft Tissue Sarcoma 69 Venous Thromboembolism 69 Report Indicates 69 TRANSFORMS 69 Pharmaceuticals Initiates 69 AS CALL VOLUME 69 Restructures Debt 69 Data Indicate 69 PATENT FOR 69 Introduces Revolutionary 69 Merge Healthcare Announces 69 Vicriviroc 69 Drug Maker 69 Completes Merger With 69 Osteoarthritis Pain 69 Newly Identified 69 Reconfirms 69 Factor Receptor 69 Successfully Concludes 69 markets COLAZAL 69 Accelerate Commercialization 69 Gene Variant 69 Novel Therapeutic 69 Patient Outcomes 69 Completes Tender Offer 69 Positive Opinion 69 Technological Advances 69 Chronic Heart Failure 69 Protein Involved 69 Net Loss Narrows 69 Renal Function 69 Blood Thinner 69 Live Attenuated 69 Beta Blocker 69 Ischemic Stroke 69 Acquisition Strengthens 69 tumor activated prodrug 69 Increased Risk 69 Idenix Novartis 69 Accelerate Adoption 69 adalimumab Humira 69 Long Term Survival 69 Announces Issuance 69 Respiratory Distress 69 Maven Semantic 69 Immunosuppressant 69 Viral Suppression 69 Nucleoside 69 R memantine HCl 69 ® bortezomib 69 Release Capsules 69 Antipsychotic Drugs 69 Achieve Significant 69 EntreMed Presents 69 Carboplatin Paclitaxel 69 diarrhea fatigue asthenia 69 Receives CE 69 REMINDER ORLive Presents 69 Metastatic Renal Cell Carcinoma 69 Delivers Next Generation 69 markets HP Acthar 69 Secures Financing 69 Clinical Evaluation 69 Helps Relieve 69 Angiotensin Converting Enzyme 69 Genes Identified 69 CYT# potent vascular disrupting 69 Antithrombin 69 PEGylated Fab fragment 69 Levoleucovorin 69 acetonide FA 69 Announce Successful Completion 69 Bullish Average Crossover 69 Gastrointestinal Disorders 69 developing Bicifadine serotonin 69 Clinically Significant 69 Amgen Neulasta R 69 R metformin Concor 69 PROVENGE ® 69 AvalonBay Communities Announces 69 Secures Additional 69 Ranolazine 69 Announce Settlement 69 Unresectable 69 J Am Acad 69 Plus Ribavirin 69 Subsidiary Enters 69 Guides FY# Update 69 Announces Dismissal 69 Antibody Drug Conjugate 69 Hedgehog Pathway 69 Urinary Tract Infections 69 Left Ventricular Hypertrophy 69 Preterm Labor 69 Gene Mutation 69 Sixth Consecutive Quarter 69 Cinacalcet 69 Embolic Protection 69 Stent Placement 69 Resistant Hypertension 69 Provides Updates 69 Significantly Improve 69 SIDE EFFECTS CHEAP ONLINE 69 FDA Warns 69 Experiences Significant 69 induced macular edema 69 Results Confirm 69 Hypercholesterolemia 69 Radical Prostatectomy 69 Physician Insights 69 Taxane 69 Hepatocellular Carcinoma 69 erlotinib Tarceva R 69 refractory chronic lymphocytic 69 CHEAP ONLINE PHARMACY LOW 69 R Bortezomib 69 Significantly Enhances 69 formerly LymphoStat B 69 Gene Mutations 69 Epidermal Growth Factor Receptor 69 IMiDs ® 69 pralatrexate injection folate analogue 69 Epoetin Alfa 69 Glufosfamide 69 Q1 Loss Widens 69 TREATMENT OF 69 Genes Associated 69 Guidance Quick Facts 69 Vitamin D Linked 69 Breast Cancer Cells 69 beta 1a 69 Weight Loss Drug 69 Being Studied 69 R famotidine 69 Fuwei Films Announces 69 Clarifies Status 69 Moxifloxacin 69 Terminate Merger Agreement 69 Ecallantide 69 Appoints Seasoned 69 Am J Clin 69 Boxed Warnings 69 Fludara ® 69 Cardiac Function 69 Announces Stockholder Approval 69 Statin Therapy 69 Appoints Experienced